Canagliflozin

Drug Profile

Canagliflozin

Alternative Names: Canagliflozin-hydrate; Canaglu; Invokana; JNJ-28431754; Sulisent; TA-7284

Latest Information Update: 22 May 2017

Price : $50

At a glance

  • Originator Tanabe Seiyaku
  • Developer Daiichi Sankyo Company; Johnson & Johnson; Mitsubishi Tanabe Pharma Corporation
  • Class Antihyperglycaemics; Glucosides; Small molecules; Thiophenes
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Diabetic nephropathies
  • Phase II Obesity; Type 1 diabetes mellitus

Most Recent Events

  • 16 May 2017 The US FDA issues boxed warning for canagliflozin to include increased risk of leg and foot amputation in Type 2 diabetes mellitus
  • 16 May 2017 Final adverse events data from the phase III CANVAS and CANVAS-R trials in Type 2 diabetes mellitus were released
  • 15 May 2017 No development reported - Phase-III for Type-2 diabetes mellitus in South Africa (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top